Celcuity (NASDAQ:CELC) Hits New 12-Month High - Should You Buy?

Key Points

• Celcuity's stock reached a new 52-week high on Thursday, trading as high as $55.25 and closing at $54.09, marking a significant increase from its previous close of $49.96.
• Analysts maintain a consensus rating of "Buy" for Celcuity, with adjusted target prices ranging from $30.00 to $70.00, reflecting optimism about the company's future performance.
• Celcuity recently reported a quarterly EPS of ($1.04), falling short of the expected consensus of ($0.90), as analysts forecast a yearly EPS of -2.62.

Celcuity, Inc. (NASDAQ:CELC - Get Free Report)'s stock price reached a new 52-week high on Thursday . The company traded as high as $55.25 and last traded at $54.09, with a volume of 81125 shares traded. The stock had previously closed at $49.96.

Analyst Ratings Changes

A number of analysts have recently weighed in on CELC shares. Needham & Company LLC reduced their target price on shares of Celcuity from $74.00 to $70.00 and set a "buy" rating on the stock in a research report on Friday, August 15th. HC Wainwright upped their target price on shares of Celcuity from $50.00 to $66.00 and gave the stock a "buy" rating in a research report on Monday, August 18th. Leerink Partners upped their target price on shares of Celcuity from $28.00 to $60.00 and gave the stock an "outperform" rating in a research report on Monday, July 28th. Finally, Stifel Nicolaus started coverage on shares of Celcuity in a research report on Tuesday, July 1st. They issued a "buy" rating and a $30.00 target price on the stock. Four analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Celcuity presently has a consensus rating of "Buy" and an average target price of $56.50.

Celcuity Stock Up 9.8%

The company's 50-day moving average is $28.48 and its 200 day moving average is $16.86. The company has a market capitalization of $2.33 billion, a PE ratio of -15.90 and a beta of 0.68. The company has a debt-to-equity ratio of 2.24, a quick ratio of 4.58 and a current ratio of 4.58.

Celcuity (NASDAQ:CELC - Get Free Report) last announced its quarterly earnings results on Thursday, August 14th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.90) by ($0.14). As a group, analysts anticipate that Celcuity, Inc. will post -2.62 EPS for the current year.

Insider Activity

In other news, Director David Dalvey sold 100,000 shares of the firm's stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $43.98, for a total transaction of $4,398,000.00. Following the sale, the director owned 125,000 shares of the company's stock, valued at $5,497,500. This trade represents a 44.44% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 15.77% of the stock is currently owned by insiders.

Institutional Trading of Celcuity

A number of institutional investors have recently made changes to their positions in CELC. BNP Paribas Financial Markets boosted its holdings in shares of Celcuity by 78.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company's stock valued at $35,000 after acquiring an additional 1,167 shares during the last quarter. Aquatic Capital Management LLC bought a new position in shares of Celcuity in the 4th quarter worth approximately $50,000. Tower Research Capital LLC TRC lifted its stake in shares of Celcuity by 211.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,549 shares of the company's stock worth $74,000 after purchasing an additional 3,766 shares during the period. AlphaQuest LLC lifted its stake in shares of Celcuity by 176.3% in the 2nd quarter. AlphaQuest LLC now owns 7,087 shares of the company's stock worth $95,000 after purchasing an additional 4,522 shares during the period. Finally, Focus Financial Network Inc. bought a new position in shares of Celcuity in the 1st quarter worth approximately $108,000. Hedge funds and other institutional investors own 63.33% of the company's stock.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.